Postoperative Versus Preoperative Initiation of Deep-Vein Thrombosis Prophylaxis with a Low-Molecular-Weight Heparin (Nadroparin) in Elective Hip Replacement

Abstract

The aim of this multicenter, randomized, dou ble-blind study performed in patients undergoing elective hip surgery was to compare the efficacy and safety of prophylaxis with low-molecular-weight heparin (LMWH) (Nadroparin, 7,500 anti-Xa IC units for the first 3 days and 10,000 from the fourth day on, s.c. o.i.d.) begun in one group shortly after surgery and in the other 12 h before operation, as is usually recommended. Preopera tive administration (drug or placebo) was the only differ ence between the two groups. Deep vein thrombosis (DVT) was detected by bilateral venography 10-15 days after surgery. The study investigated 179 patients (55 men), 40-80 years old, in seven Italian orthopedic cen ters. In 131 patients efficacy analysis was possible be cause of adequate bilateral venography. All 179 patients were evaluated for bleeding complications. The preva lence of thrombotic complications was similar in the two groups. Proximal DVT was found in 8.4% of patients (10.8% and 6.1% in the preop and postop groups, respec tively ; difference not statistically significant). Distal DVT was recorded in 30.5% of patients (30.8% and 30.3% in the pre- and postop groups, respectively). DVTs were more common in patients ≥65 years old (54.2% versus 28.4%, p < 0.05); no significant differences were detected in terms of other characteristics. No significant differ ences were recorded in the number or type of bleeding complications: major (nonfatal) bleeding episodes were reported in five patients (2.8%, two and three in the pre- and postop groups); minor bleeding was noted in 25 (13.9%, 14 and 11 in the pre- and postop groups). In con clusion, the present study suggests that a LMWH regi men started postoperatively is no less effective in pre venting DVT in elective hip replacement than the classi cal regimen started preoperatively. Surprisingly, postoperative commencement offered no significant ad vantage in terms of bleeding complications.

Keywords

Key Words: Low-molecular-weight heparin Deep vein thrombosis Prophylaxis Hip replacement Bleeding complications.

Get full access to this article

View all access options for this article.

References

Clagett GP , Anderson FA , Levine MN , Salzman EW , Wheeler HB Prevention of venous thromboembolism. Chest 1992;102:391S-407S.

Haake DA , Berkman SA Venous thromboembolic disease after hip surgery: risk factors, prophylaxis, and diagnosis. Clin Orthop Rel Res 1989;242:212-31.

Laverick MD , Croal SA , Mollan Rab. Orthopaedic surgeons and thromboprophylaxis. Br Med J 1991;303:549-50. 4. Turpie Agg , Levine MN , Hirsh J. , et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986;315:925-9.

Levine MN , Hirsh J. , Gent M. , et al. Prevention of deep vein thrombosis after elective hip surgery: a randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991;114:545-51.

Planes A. , Vochelle N. , Fagola M. , Feret J. Bellaud M. Prevention of deep vein thrombosis after total hip replacement: the effect of low-molecular-weight heparin with spinal and general anesthesia . J Bone Joint Surg 1991;73-B:418-22.

Leclerc JR , Geerts WH , Desjardins L. , et al. Prevention of deep vein thrombosis after major knee surgery: a randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992;67:417-23.

Leyvraz PF , Bachmann F. , Hoek J. , et al. Prevention of deep vein thrombosis after hip replacement: randomized comparison between unfractionated heparin and low molecular weight heparin . Br Med J 1991;303:543-8.

Rabinov K. , Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Arch Surg 1972;104:134-44.

Sharrock NE , Brien WW , Salvati EA , Mineo R. , Garvin K. , Sculco TP The effect of intravenous fixed-dose heparin during total hip arthroplasty on the incidence of deep-vein thrombosis: a randomized, double-blind trial in patients operated on with epidural anesthesia and controlled hypotension. J Bone Joint Surg 1990;72A: 1456-61.

10.

Nurmohamed MT , Rosendaal FR , Buller HR , et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis . Lancet 1992;340: 152-6.

11.

Hirsh J. , Levine MN Low molecular weight heparin. Blood 1992;79:1-17.

12.

Council on Thrombosis of the American Heart Association. Prevention of venous thromboembolism in surgical patients by low-dose heparin. Circulation 1977;55:423A.

13.

Colditz GA , Tuden RL , Oster G. Rates of venous thrombosis after general surgery: combined results of randomized clinical trials. Lancet 1986 ; 1:143-6.

14.

Collins R. , Scrimgeour A. , Yusuf S. , et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988;318:1162-73.

15.

The German Hip Arthroplasty Trial (GHAT) Group. Prevention of deep vein thrombosis with low-molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. Arch Orthop Trauma Surg 1992;111:110-20.

16.

Hirsh J. , Hull RD Venous thromboembolism: natural history, diagnosis, and management. Boca Raton: CRC Press, 1987:76.

17.

Lassen MR , Borris LC , Christiansen HM , et al. Heparin/ dihydroergotamine for venous thrombosis prophylaxis: comparison of low-dose heparin and low molecular weight heparin in hip surgery . Br J Surg 1988;75:686-9.

18.

Planes A. , Vochelle N. , Bouthier J. , Fagola M. , Bellaud M. Use of enoxaparin, a low molecular weight heparin, in elective hip surgery . Semin Thromb Hemost 1991;17:296-303.

19.

Hoek JA , Nurmohamed MT , Hamelynck KJ , et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 1992; 67:28-32.

20.

Drouet JC , Bernard JM , Bourreli B. , Gunst JP Low-molecular-weight heparin (Fraxiparine) to prevent deep vein thrombosis in patients undergoing orthopaedic surgery: a clinical report of two regimens . Haemostasis 1988;18:135-6.

21.

Vitoux JF , Aiach M. , Roncato M. , Fiessinger JN

Should thromboprophylactic dosage of low molecular weight heparin be adapted to patient's weight?

Thromb Haemost 1988; 59:120.